Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Phase 3
Completed
- Conditions
- CancerMultiple MyelomaBone MetastasesOncologyHematologic MalignanciesMultiple Myeloma Bone Lesions
- Interventions
- Drug: Placebo to DenosumabDrug: Placebo to zoledronic acid
- First Posted Date
- 2011-04-29
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1718
- Registration Number
- NCT01345019
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
Phase 1
Completed
- Conditions
- Kidney DiseaseRenal ImpairmentAdvanced Solid Tumors
- Interventions
- Drug: AMG 386 + Paclitaxel
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT01331941
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Biological: etanerceptDrug: Topical agents
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-03-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 310
- Registration Number
- NCT01313221
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-03-11
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 210
- Registration Number
- NCT01313208
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Phase 3
Completed
- Conditions
- Psoriatic Arthritis
- Interventions
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 529
- Registration Number
- NCT01307423
- Locations
- 🇺🇸
Unifour Medical Research Associatets LLC, Hickory, North Carolina, United States
🇺🇸Rockford Orthopedic Associates, LLC, Rockford, Illinois, United States
🇺🇸Atlanta Dermatology, Vein and Research Center, PC, Alpharetta, Georgia, United States
A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 315
- Registration Number
- NCT01302392
AMG 319 Lymphoid Malignancy FIH
Phase 1
Completed
- Conditions
- CancerChronic Lymphocytic LeukemiaDiffuse Large Cell LymphomaHematologic MalignanciesHematologyLeukemiaLow Grade LymphomaLymphomaMantle Cell LymphomaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Amgen
- Target Recruit Count
- 28
- Registration Number
- NCT01300026
- Locations
- 🇺🇸
Research Site, Salt Lake City, Utah, United States
To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT01300208
- Locations
- 🇺🇸
Medderm Associates, San Diego, California, United States
🇺🇸Central Dermatology, P.C., Saint Louis, Missouri, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Effects of Denosumab on the Pharmacokinetics of Etanercept
Phase 1
Terminated
- Conditions
- OsteopeniaRheumatoid ArthritisPostmenopausalOsteoporosis
- Interventions
- First Posted Date
- 2011-02-11
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 19
- Registration Number
- NCT01294397
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.
Phase 1
Completed
- Conditions
- Ulcerative ColitisCrohn's Disease
- Interventions
- Other: Placebo for AMG 181
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2015-03-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT01290042
- Locations
- 🇦🇺
Research Site, Prahran, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath